Business Context and Reporting Period
This Form 6-K filing by Belite Bio, Inc. covers the month of September 2025, specifically dated September 8, 2025. The report details a significant corporate action: the entry into Securities Purchase Agreements for a private placement in public equity financing (PIPE) with leading healthcare investors.
Key Financial Metrics and Transaction Details
The filing outlines the following financial terms for the PIPE transaction:
- Gross Proceeds: Approximately $125 million from the initial sale, before deducting placement agent fees and offering expenses.
- Securities Issued: 1,953,124 ordinary shares and warrants to purchase an equal number of ordinary shares (1,953,124).
- Purchase Price: $64.00 per ordinary share and accompanying warrant.
- Warrant Terms: Immediately exercisable with an exercise price of $76.80 per share; expiration is two years from issuance.
- Potential Additional Proceeds: Approximately $150 million if all warrants are exercised in full.
- Closing Date: Expected on or about September 9, 2025, subject to customary conditions.
The filing does not provide current revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the financing event.
Material Changes and Agreements
In connection with the PIPE, the Company and Investors entered into a Registration Rights Agreement dated September 8, 2025. Key provisions include:
- The Company must file a registration statement for the resale of shares and warrant-issued shares with the SEC no later than 45 days after the Closing Date.
- The Company must use reasonable best efforts to have the registration statement declared effective by the earlier of the 75th calendar day after filing or the fifth business day after notification of no further SEC review.
- The securities are issued under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D exemptions and are not registered for public sale until the registration statement becomes effective.
Outlook, Risks, and Management Commentary
Management, represented by CEO and Chairman Yu-Hsin Lin, has authorized this filing to disclose the financing. The transaction is contingent on the satisfaction of customary closing conditions. The filing notes that the securities may not be offered or sold in the United States absent registration or an applicable exemption. No specific operational guidance or risk factors beyond standard transaction contingencies are detailed in this specific text.
Investor Verification Checklist
- Verify the final closing of the PIPE transaction on or about September 9, 2025.
- Confirm the filing and effectiveness of the Registration Statement within the 45-day and 75-day windows specified in the Registration Rights Agreement.
- Review the full text of the Securities Purchase Agreements (Exhibit 10.1) and Warrants (Exhibit 4.1) for specific covenants and indemnification obligations.
- Monitor the press release (Exhibit 99.1) for any updates on the identity of the "leading healthcare investors."
- Assess the impact of the $125 million gross proceeds on the company's liquidity and runway, noting that net proceeds will be lower after fees.